Literature DB >> 10958659

CREB-binding protein sequestration by expanded polyglutamine.

A McCampbell1, J P Taylor, A A Taye, J Robitschek, M Li, J Walcott, D Merry, Y Chai, H Paulson, G Sobue, K H Fischbeck.   

Abstract

Spinal and bulbar muscular atrophy (SBMA) is one of eight inherited neurodegenerative diseases known to be caused by CAG repeat expansion. The expansion results in an expanded polyglutamine tract, which likely confers a novel, toxic function to the affected protein. Cell culture and transgenic mouse studies have implicated the nucleus as a site for pathogenesis, suggesting that a critical nuclear factor or process is disrupted by the polyglutamine expansion. In this report we present evidence that CREB-binding protein (CBP), a transcriptional co-activator that orchestrates nuclear response to a variety of cell signaling cascades, is incorporated into nuclear inclusions formed by polyglutamine-containing proteins in cultured cells, transgenic mice and tissue from patients with SBMA. We also show CBP incorporation into nuclear inclusions formed in a cell culture model of another polyglutamine disease, spinocerebellar ataxia type 3. We present evidence that soluble levels of CBP are reduced in cells expressing expanded polyglutamine despite increased levels of CBP mRNA. Finally, we demonstrate that over-expression of CBP rescues cells from polyglutamine-mediated toxicity in neuronal cell culture. These data support a CBP-sequestration model of polyglutamine expansion disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10958659     DOI: 10.1093/hmg/9.14.2197

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  147 in total

1.  Novel therapies in the search for a cure for Huntington's disease.

Authors:  M F Beal; P Hantraye
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

2.  Glutamine/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity.

Authors:  Peter W Faber; Cindy Voisine; Daphne C King; Emily A Bates; Anne C Hart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-16       Impact factor: 11.205

Review 3.  Developing treatment for spinal and bulbar muscular atrophy.

Authors:  Kenneth H Fischbeck
Journal:  Prog Neurobiol       Date:  2012-06-02       Impact factor: 11.685

Review 4.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

5.  Polyglutamine fibrillogenesis: the pathway unfolds.

Authors:  Christopher A Ross; Michelle A Poirier; Erich E Wanker; Mario Amzel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-30       Impact factor: 11.205

6.  SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA.

Authors:  Heather L Montie; Richard G Pestell; Diane E Merry
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

Review 7.  Therapeutic approaches to spinal and bulbar muscular atrophy.

Authors:  Srikanth Ranganathan; Kenneth H Fischbeck
Journal:  Trends Pharmacol Sci       Date:  2010-09-20       Impact factor: 14.819

8.  Development of histone deacetylase inhibitors as therapeutics for neurological disease.

Authors:  Joel M Gottesfeld; Massimo Pandolfo
Journal:  Future Neurol       Date:  2009-11-01

Review 9.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

10.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis.

Authors:  Kristina Becanovic; Mahmoud A Pouladi; Raymond S Lim; Alexandre Kuhn; Paul Pavlidis; Ruth Luthi-Carter; Michael R Hayden; Blair R Leavitt
Journal:  Hum Mol Genet       Date:  2010-01-20       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.